Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Acerand Therapeutics Reports ...
July 28 (UPI) --Some drugs prescribed to people with high blood pressure and congestive heart failure weaken the immune system's ability to fight off bacterial infections, a study published Wednesday ...
ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a new ...
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone and muscle, and Celgene Corporation ...
DETROIT – A new Henry Ford Hospital study takes a closer look at one of the lesser known, but potential most serious side-effects of ACE inhibitor use – facial, tongue and airway swelling – and ...
Acceleron earns $10 million milestone payment from collaboration partner Celgene Corporation Cambridge, Mass. – January 29, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing ...
Acerand Therapeutics Reports Promising Clinical Activity and Favorable Safety Profile for ACE-106, a Potential Best-in-Class PARP1 Selective Inhibitor SHANGHAI & INDIANAPOLIS, April 16, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results